Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06875700 · ClinicalTrials.gov registry record
Beliefs, Attitudes, and Response to Genetic Testing in SarcomaPatients
A clinical trial of Leiomyosarcoma, sponsored by University of Utah.
- Recruiting
- Registry status
- 300
- Enrollment target
- 1
- Study location
NCT06875700 is a study of Leiomyosarcoma that is actively recruiting participants, run by University of Utah. The registered enrollment target is 300 participants, above the 103-participant average among 16 other Leiomyosarcoma trials with a reported enrollment target (191% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06875700, a study of Leiomyosarcoma, is actively recruiting participants, sponsored by University of Utah.
- RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
Genomic research has shown that a portion of leiomyosarcomas can be attributed to an underlying cancer predisposition syndrome. However, the optimal approach for incorporating germline testing into the care of these patients. This study is assessing the beliefs about the heritability of leiomyosarcoma and other cancer risks, and attitudes towards germline testing among leiomyosarcoma patients.
Conditions Studied
Study Locations (1)
Utah
- Huntsman Cancer Institute at the University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2024-07-09 |
| Est. Completion | 2027-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06875700
The ClinicalTrials.gov registry entry for NCT06875700 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 103-participant average among 16 other Leiomyosarcoma trials with a reported enrollment target (191% higher). The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Leiomyosarcoma appearing as the primary indexed condition, and to 0 interventions.
NCT06875700 reports 1 study location spanning 1 distinct geographic area - top geographies include Utah.
Frequently Asked Questions
What is clinical trial NCT06875700 about?
NCT06875700 is a clinical study titled "Beliefs, Attitudes, and Response to Genetic Testing in SarcomaPatients". Genomic research has shown that a portion of leiomyosarcomas can be attributed to an underlying cancer predisposition syndrome. However, the optimal approach for incorporating germline testing into the care of these patients. This study is assessing the beliefs about the heritability of leiomyosarco...
What is the current status of trial NCT06875700?
This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2024-07-09. Estimated completion is 2027-08.
What conditions does trial NCT06875700 study?
This clinical trial studies the following conditions: Leiomyosarcoma.
Who is sponsoring clinical trial NCT06875700?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06875700 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leiomyosarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Localized Leiomyosarcoma Biomarker Protocol
RECRUITING
-
Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)
RECRUITING · Phase 3
-
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
RECRUITING · Phase 3
-
Metastatic Leiomyosarcoma Biomarker Protocol
RECRUITING
-
Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma
RECRUITING · Phase 2
-
Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Soft Tissue Sarcoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.